In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
In the VERIFY study rusfertide demonstrated both safety and efficacy in reducing phlebotomy dependence for patients with polycythemia …
A new international trial aims to confirm the benefit of adding masitinib to chemotherapy in men with metastatic …
New option opens for patients who have exhausted several therapies in their fight against relapsed or refractory multiple …
Company Overview and Focus Biodexa Pharmaceuticals PLC, a clinical-stage biotechnology company dedicated to developing innovative treatments for diseases …
Continued program expansion strengthens potential to deliver an all-oral, pan-genotypic next-generation HCV therapy.
Dual GLP-1 and GIP receptor agonist VK2735 moves into pivotal trials targeting robust weight loss and glycemic control …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
New clinical findings support dapiglutide’s potential as first-in-class injectable therapy; CEO touts “milestone in multi-receptor peptide innovation”.
Already a subscriber? Log in